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Abstract The light and heavy chain variable regions of three
mouse hybridoma cell lines (AG11, AE6 and EH1) that produce
monoclonal antibodies against an overlapping epitope at the C-
terminus of Nef were cloned. Sequence analysis of the light and
heavy chain variable regions indicated that clones AG11 and
AE6, but not EH1, were highly related. Single-chain antibodies
were constructed from the cDNA clones of AG11 and EH1, and
subcloned into an eukaryotic expressing vector with the green
fluorescent protein as marker for expression. Such intracellular
antibodies may provide a way in which to inhibit the function of
Nef during HIV-1 infection of cells.
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1. Introduction
Nef is an accessory protein produced at all stages of human
immunode¢ciency virus-1 (HIV-1) gene expression. Although
initially Nef was described as being able to repress viral gene
transcription [1], these results were not con¢rmed by subse-
quent investigations [2,3]. Studies in peripheral blood mono-
nuclear cells (PBMC) [4^7], in speci¢c T-cell lines [8], in rhesus
monkeys infected with nef-deleted strains of simian immuno-
de¢ciency virus [9], and in some of the long-term non-pro-
gressors of HIV-1 infection [10,11], demonstrated that Nef is
not only necessary for rapid HIV-1 replication in vitro, but
that it is also required for e⁄cient viral growth in vivo. How-
ever, the precise role of Nef in these processes has not been
fully elucidated.
One approach to study the function of cytosolic proteins
involves the use of intracellular single-chain antibodies (ScFv)
that either block function or sequester the protein of interest.
ScFv, which have been shown to have speci¢c binding a⁄n-
ities equivalent to those of the parent monoclonal antibodies
[12,13], can be stably expressed intracellularly where they are
capable of inactivating speci¢c cellular gene products [14,15].
Intracellular ScFv proteins with speci¢city for virally encoded
proteins thus provide a unique way of studying the role of
these viral proteins in HIV-1 infection [16], as well as o¡ering
a potential gene therapy strategy for inhibiting the develop-
ment of AIDS.
We report the cloning and sequencing of the antibody var-
iable regions of three hybridoma cell lines, as well as subse-
quent ScFv construction and expression. All cell lines studied
produced monoclonal antibodies speci¢c to an overlapping
epitope at the C-terminus of Nef protein. Single-chain anti-
bodies were then constructed by tethering the VU and VH
genes to a DNA sequence encoding a 15 amino acid peptide
(GGGGS)3. A green £uorescent protein (GFP) fusion was
used as a reporter for monitoring intracellular expression of
the single-chain antibodies. Immunoprecipitation studies dem-
onstrated that the ScFv retained the binding activity of their
corresponding parent monoclonal antibodies.
2. Materials and methods
2.1. Nef-speci¢c monoclonal antibodies
Anti-Nef hybridoma clones AG11 and AE6 were raised against the
recombinant Nef protein of HIV-1LAI strain and were both derived
from the same fusion. They both produce IgG1 monoclonal antibod-
ies that recognize Nef of the HIV-1LAI, but not SF2 strain, and are
speci¢c for the C-terminus of Nef (epitope: VARELHPEYFKNC)
(unpublished data). Clone EH1, raised against the Nef protein of
the HIV-1SF2 strain, is an IgG1 monoclonal antibody that reacts
with Nef from both HIV-1 LAI and SF2 strains. It was also mapped
to the C-terminus of Nef protein (epitope: MARELHPEYYKDC)
(unpublished data).
2.2. Inhibition ELISA assay
Recombinant Nef-GST (a gift from Dr. Mark Harris) [17] used as
the coating antigen was derived from HIV-1BH10. Nef from HIV-1BH10
shares 96% identity with the amino acid sequence of HIV-1LAI. Micro-
titer wells were coated with 50 Wl of Nef-GST per well (12.5 Wg/ml in
PBS bu¡er) overnight at 4‡C. The wells were blocked with 1% BSA/
PBS for 1 h at 37‡C. MAb from clone EH1 was biotinylated using the
ImmunoPure Sulfo NHS-LC-Biotinylation Kit (Pierce). Serially di-
luted antibodies from clones AG11 and AE6, as well as a mAb
(F14.11) generated against a di¡erent epitope of Nef (Nef83ÿ88 :
AAVDLS) [18], were mixed with 5 Wg/ml biotinylated EH1 mAb in
the wells and incubated for 1 h at 37‡C. After three washes with
0.05% Tween 20/PBS, avidin-alkaline phosphatase (Pierce) was added
at a dilution of 1:1000 and incubated at 37‡C for 1 h and washed as
above. Immune complexes were detected by the enzyme-substrate re-
action with p-nitrophenyl phosphate (Sigma), with the reactions being
read at 405 nm after 30 min.
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2.3. RNA isolation and reverse transcription-polymerase chain reaction
Total RNA was isolated from 107 hybridoma cells, using the gua-
nidinium thiocyanate method [19]. The variable regions of the light
chain and heavy chain were ampli¢ed by RT-PCR, using the follow-
ing primers: forward primers: VUForward (5P AAGCTTCCATGG-
A[CT][AG]T[TC][TG][TA]GATGAC[CA]CA[GA][TA]CTCC 3P), VH-
Forward (5PGGATCCGGTGGTGGTGGTTCTGGTGGTGGTGG-
TG[AG]GGT[CG]CA[AG]CT[GT][GC][TA]G[GC]AGTC[AT]GG3P) ;
and reverse primers: VUReverse (5P GGATCCACCACCACCATT-
GATTTCCAGCTTGGTGCCAGCACCGAACG 3P), VHReverse (5P
AAGCTTCTATGAGGAGACGGTGACCGTGGTCCCGGGGCC-
CCAG 3P). Primers VUForward and VHForward are degenerate prim-
ers with alternative bases indicated in the brackets. The synthesis of
cDNA was performed using Superscript Moloney leukemia virus
(M-MLV) reverse transcriptase (Gibco BRL/Life Technologies) ac-
cording to the manufacturer’s instructions. The reverse primers were
used to prime the reverse transcription reactions. Polymerase chain
reactions (PCR) were then performed using Taq DNA polymerase
(Perkin-Elmer Cetus) in a GeneAmp PCR System 9600 (Perkin Elmer
Cetus), for 35 cycles under the following conditions: denaturation at
96‡C for 30 s, annealing at 58‡C for 45 s, and extension at 72‡C for
1 min; ¢nishing with 72‡C for 10 min.
2.4. Cloning and sequencing of ampli¢ed products
Ampli¢ed DNA fragments were digested with BamHI and HindIII
and gel puri¢ed by electrophoresis on 1.5% agarose gels, using the
QIAquick gel extraction kit (Qiagen). The puri¢ed products were
ligated into the BamHI/HindIII restriction sites of a cloning vector,
pGEM-4Z (Promega), and transformed into DH10B competent bac-
teria (Gibco BRL). Several recombinant clones were selected and
sequenced in both directions using dye terminator cycle sequencing
kit (Applied Biosystems), and T7/SP6 promoter primers (University
Core DNA Services, University of Calgary, Canada) on a 373 auto-
mated sequencer (Applied Biosystems). Alignment of the antibody
sequences was performed using Clustal V [20]. Sequences of the re-
combinant clones were also compared with the non-redundant data-
base at National Center for Biotechnology Information (NCBI) using
the Blast program [21].
2.5. Construction and expression of ScFv tagged with GFP
The ScFv were constructed by ligating the VU and VH DNA frag-
ments via the BamHI site at the 3P end of VU and 5P end of VH. PCR
was used to add the Kozak sequence, GCCACC [22], the start codon,
and the restriction sites, EcoRI and NheI, to the 5P and 3P ends of the
ScFv constructs, respectively. The primers used are: forward primer,
GGAATTCCTGCCACCATGGACATTTTGATGACCCAGTCT;
reverse primer, CGCCTAGCTAGCTGAGGAGACGGTGACCG.
PCR products were subsequently cloned into a mammalian expression
vector, pcDEF-GFP, constructed from pcDEF3 [23] and pQBI25
(Quantum). The resulting pDEF-ScFv-GFP vector has a EF-1K pro-
moter and GFP reporter gene at the C-terminus of the expression
cassette (Fig. 4). HEK 293 cells were transfected with pcDEF-ScFv-
GFP using Superfect (Qiagen).
2.6. Fluorescent microscopy
HEK 293 cells were transfected and cultured overnight in Chamber
Slides (Lab-Tek, Nunc). The slides were then washed three times with
PBS and ¢xed for 10 min in 4% paraformaldehyde at room temper-
ature. After three PBS washes, the slides were mounted with Gel/Tol
Aqueous Mounting Medium (Immunon, Fisher), and sealed with nail
polish. A £uorescent microscope (Zeiss) and CCD camera were used
to monitor the GFP fusion protein expression.
2.7. Characterization of expressed ScFv by immunoprecipitation
HEK 293 cells were transfected and cultured overnight in 6-well
tissue culture plates (Nunclon Surface, Nunc), and then washed
once with cold PBS and lysed in 1 ml of lysis bu¡er (0.5% NP-40,
100 mM NaCl, 25 mM Tris, pH 7.5, 2 mM EDTA, 10% glycerol, 50
mM NaF, and 10 Wg/ml of each of the protease inhibitors: leupeptin,
aprotinin, soybean trypsin inhibitor). The supernatant was ¢rst
cleared of cell debris by centrifugation and subsequently pre-cleared
by GST (a gift from Dr. Mark Harris) cross-linked to Sepharose
beads (CNBr-activated Sepharose 4B, Pharmacia). The recombinant
Nef-GST fusion protein cross-linked to Sepharose beads was used to
immunoprecipitate ScFv by incubating for 1 h with rotation at 4‡C.
The precipitated products were resolved by SDS-PAGE electrophore-
sis and transferred onto a nitrocellulose membrane. The membrane
was then blocked with 5% skim milk in TBS-T bu¡er (10 mM Tris, 50
mM NaCl, and 0.5% Tween 20) and probed with anti-GFP antibody
(1:4000 dilution, Boehringer Mannheim). Immunodetection was ac-
complished using goat anti-mouse antibody conjugated to horseradish
peroxidase, washed with TBS-T and followed by ECL detection
(Amersham). The membrane was subsequently exposed to X-ray
¢lm (X-OMAT, Kodak).
3. Results
3.1. AG11 and AE6 mAbs bind to an overlapping epitope with
mAbs of clone EH1
Using the binding inhibition ELISA assay, it was shown
that mAbs from clones AG11 and AE6 inhibited the binding
of the biotinylated EH1 mAb to immobilized Nef protein
(Fig. 1). This binding inhibition was speci¢c, since another
mAb, F14.11, that was mapped to a di¡erent epitope failed
to inhibit the binding of biotinylated EH1 mAb to immobi-
lized Nef.
3.2. Cloning and sequencing of mouse IgG variable regions
The variable regions of light and heavy chains were cloned
from the mouse anti-Nef monoclonal antibody producing hy-
bridoma clones, AG11, AE6 and EH1. At least three clones
from two independent RT-PCR reactions were sequenced to
minimize the possibility of errors introduced during the am-
pli¢cation step.
A second aberrant VU transcript was identi¢ed in all three
hybridoma cell lines as described [24,25]. Using primers spe-
ci¢c for the CDR-1 and CDR-3 regions of the Sp2/0 endog-
enous U chain variable region, we were able to eliminate plas-
mids containing the aberrant U chain cDNA using the colony
PCR method [24]. An internal HindIII site was found in the
PCR ampli¢ed U chain (between CDR-2 and CDR-3, at posi-
tion 206, Fig. 2A) from clone EH1. Therefore, the TA cloning
vector (Invitrogen), instead of pGEM-4Z, was used to sub-
clone this cDNA.
Sequences from the three hybridoma cell lines were then
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Fig. 1. Binding inhibition of biotinylated EH1 mAb by unlabeled
AG11 (8) and AE6 (R) mAbs. F14.11 (a) was a control mAb.
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analyzed. The aligned DNA and predicted amino acid se-
quence of the light chain and heavy chain variable regions
are shown in Figs. 2 and 3. The complementarity determining
regions (CDRs) were de¢ned according to the Kabat-Wu
numbering scheme [26].
All of the sequences of the variable regions from the three
hybridomas contained open reading frames. At the DNA lev-
el, the total CDRs of clone AG11 was 95.1% similar to that of
clone AE6. Both antibodies recognize the C-terminus of Nef
from LAI strain (Table 1). The total CDRs of clone AG11, in
contrast, was only 57.9% similar to clone EH1, which recog-
nizes an overlapping epitope at the C-terminus of Nef (Table
1). A low percentage of sequence similarity was also found at
the amino acid level when clones AG11 and EH1 were com-
pared (Table 1). Thus, while there was 91.2% similarity when
the amino acids of the total CDRs of clones AG11 and AE6
were compared, there was only 36.8% identity when clone
AG11 was compared with EH1.
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Fig. 2. Alignment of the cDNA sequence of variable regions derived from clones AG11, AE6 and EH1. A: Light chain variable regions. B:
Heavy chain variable regions. ‘-’ denotes identical residues; ‘/’ denotes gaps. On the light chain variable region of clone EH1, there is an inter-
nal HindIII restriction site (position 206) (underlined). The complementarity determining regions are indicated.
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3.3. Construction and expression of intracellular ScFv tagged
with a GFP reporter
Single-chain antibodies (ScFv) were constructed for clones
AG11 and EH1 as described in Section 2. The cDNA of the
light chain variable region was tethered to the heavy chain
variable region through a linker DNA encoding (GGGGS)3.
The ScFv cDNA constructs were ligated to the EcoRI and
NheI sites of the pDEF-GFP expression vector (Fig. 4).
To assess the intracellularly expressed single-chain antibod-
ies, HEK 293 cells were transfected and cultured overnight.
The transfected cells were then examined using a £uorescent
microscope and attached CCD camera (Fig. 5). Comparable
level of expression was achieved with using all ScFv-GFP
constructs, as well as the control vector expressing only GFP.
The ability of the intracellularly expressed ScFv to bind
with Nef protein was assessed by immunoprecipitation of
ScFv-GFP, performed using recombinant Nef protein-immo-
bilized on Sepharose beads. The results demonstrated that the
immobilized Nef was able to precipitate intracellularly ex-
pressed ScFv-GFP (Fig. 6A), but not GFP alone (Fig. 6B,C).
4. Discussion
The technique of constructing arti¢cial antibodies by tether-
ing immunoglobulin variable regions to various linkers, com-
bined with in vitro selection strategies, o¡ers an e⁄cient route
to the development of research reagents, as well as diagnostic
and therapeutic molecules [27]. In this study, we compared the
sequences of the variable regions from three monoclonal anti-
bodies that recognize an overlapping epitope of Nef protein.
Amongst these, two of the antibody clones, AG11 and AE6,
derived from the same hybridoma fusion, were almost identi-
cal in nucleic acid and the deduced amino acid sequences.
Although the variable region sequences of EH1 clone were
signi¢cantly di¡erent from those of the other two mAbs,
EH1 recognizes an overlapping epitope within the binding
site of the AG11 and AE6 mAbs. This is supported by the
binding inhibition assay which demonstrated that the antibod-
ies from clones AG11 and AE6 inhibited the binding of the
biotin-labeled EH1 mAb to Nef protein.
The fact that EH1 antibody recognizes the recombinant Nef
from both LAI and SF2 strains, but that clones AG11 and
AE6 could only react to the Nef from LAI strain likely in-
dicated that the ¢ne speci¢city of the EH1 antibody is di¡er-
ent from that of the other two antibodies. More detailed anal-
ysis using Ala-scan mutagenesis or comparison of crystal
structures of the antibody-antigen complex would be required
to elucidate this further.
Intracellular expression of single-chain antibodies is a useful
technique for the study of cellular proteins, and may generate
potential reagents for gene therapy [28]. We have utilized a
strategy which uses green £uorescent protein [29] as a reporter
for monitoring ScFv expression in eukaryotic cells. The ad-
vantage of GFP is that the ScFv expression can be readily
monitored in either live or ¢xed cells. The binding speci¢city
of intracellularly expressed ScFv was con¢rmed by immuno-
precipitation using immobilized Nef protein.
In summary, we have successfully constructed anti-Nef sin-
gle chain antibodies which retain the binding activity of their
corresponding parental monoclonal antibodies when ex-
pressed intracellularly. Using GFP as a reporter, intracellular
ScFv expression can be readily evaluated. The anti-Nef ScFv
that we have generated can be used to study the intracellular
role of Nef in the pathogenesis of HIV-1 infection, and could
potentially be used in a gene therapy model for the treatment
of HIV-1 infection.
Acknowledgements: The authors wish to thank Drs. Kevin Leslie for
providing the primers used to amplify the variable regions of the
monoclonal antibodies; Mark Harris for the recombinant Nef-GST
fusion protein and GST protein, as well as their corresponding bacte-
rial expression vectors; Rita De Santis for the mAb clone, F14.11;
Jerome A. Langer for the pDEF-3 vector; Wayne A. Vogl for his
assistance in £uorescent microscopy. This research was supported in
part by the National Health Research and Development Program
through a National Health Fellowship to A.H.C. and also supported
by the province of British Columbia and the B.C. Centre for Excel-
lence in HIV/AIDS.
FEBS 21316 21-12-98 Cyaan Magenta Geel Zwart
Fig. 3. Deduced amino acid sequence alignment of the variable re-
gions of clones AG11, AE6 and EH1. A: Light chain variable re-
gions. B: Heavy chain variable regions. ‘-’ denotes identical resi-
dues; ‘/’ denotes gaps.
Table 1
Comparison of the variable region sequences of clones AE6 and
EH1 with AG11
Antibody Similaritya relative to clone AG11 (%)
Nucleic acid sequence Amino acid sequence
VU VH Total CDRsb VU VH Total CDRs
AE6 96.5 98.6 95.1 93.8 97.5 91.2
EH1 73.8 76.6 57.9 61.7 63.2 36.8
aThe similarity study was done according to the overlapping sequen-
ces.
bTotal CDRs: the total complementarity determining regions of both
VU and VH.
Fig. 4. The single chain antibody assembly in pDEF-GFP expres-
sion vector. A: pDEF-GFP vector which express GFP. B: pDEF-
ScFv-GFP vector which express single chain antibody-GFP fusion
protein.
A.H. Chang et al./FEBS Letters 441 (1998) 307^312310
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Fig. 5. HEK 293 cells transfected with pDEF-GFP or pDEF-ScFv-GFP, and expressing: A: GFP (phase). B: GFP (£uorescence). C: AG11
ScFv tagged with GFP (phase). D: AG11 ScFv tagged with GFP (£uorescence). E: EH1 ScFv tagged with GFP (phase). F: EH1 ScFv tagged
with GFP (£uorescence). Magni¢cation, U36.
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Fig. 6. Intracellularly expressed ScFv is immunoprecipitated by im-
mobilized recombinant Nef-GST protein. A: Immunoprecipitation
of ScFv with Nef-GST cross-linked to Sepharose beads from cells
transfected with the control vector (1), pDEF-GFP (2), pDEF-
(AG11)ScFv-GFP (3), and pDEF-(EH1)ScFv-GFP (4). B: Immuno-
blot of the total cell lysate of the cells transfected with control vec-
tor (1) and pDEF-GFP (2). C: Immunoprecipitation of cells ex-
pressing the control vector (1) and pDEF-GFP (2) corresponding to
B, by Nef-GST cross-linked with Sepharose beads.
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